Table 2 Correlation between overexpression of ezrin, ezrin Thr-567 and ezrin Tyr-353 proteins and clinical parameters of NSCLC
From: Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer
Ezrin | EzrinThr-567 | EzrinTyr-353 | |||||
|---|---|---|---|---|---|---|---|
Parameters | No. of cases | n(%) | P | n(%) | P | n(%) | P |
Gender | 0.062 | 0.45 | 0.230 | ||||
  Male | 112 | 75 (67.0) | 69 (61.6) | 77 (68.8) | |||
  Female | 38 | 19 (50.0) | 26 (68.4) | 30 (78.9) | |||
Age | 0.077 | 0.642 | 0.364 | ||||
  ≧60 | 99 | 67 (67.7) | 64 (64.6) | 73 (73.7) | |||
  <60 | 51 | 27 (52.9) | 31 (60.8) | 34 (66.7) | |||
Tumor size | 0.283 | .791 | 0.620 | ||||
  T1-2 | 119 | 72 (60.5) | 76 (63.9) | 86 (72.3) | |||
  T3-4 | 31 | 22 (71.0) | 19 (61.3) | 21 (67.7) | |||
Stage | 0.000** | .031* | 0.000** | ||||
  I-II | 98 | 51 (52.0) | 56 (57.1) | 59 (60.2) | |||
  III-IV | 52 | 43 (82.7) | 39 (75.0) | 48 (92.3) | |||
Differentiation | 0.007 a ** | 0.002 a ** | 0.006 a ** | ||||
  Well | 34 | 17 (50.0) | 16 (47.1) | 21 (61.8) | |||
  Moderate | 89 | 54 (60.7) | 55 (61.8) | 61 (68.5) | |||
  Poor | 27 | 23 (85.2) | 24 (88.9) | 25 (92.6) | |||
LN metastasis | 0.318 | 0.002** | 0.578 | ||||
  Negative | 96 | 63 (65.6) | 52 (54.2) | 67 (69.8) | |||
  Positive | 54 | 31 (57.4) | 43 (79.6) | 40 (74.1) | |||